Identification

Summary

Magnesium trisilicate is an antacid used for the symptomatic treatment of peptic ulcers.

Generic Name
Magnesium trisilicate
DrugBank Accession Number
DB09281
Background

Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 260.857
Monoisotopic: 259.86017997
Chemical Formula
Mg2O8Si3
Synonyms
  • Magnesio trisilicato

Pharmacology

Indication

For the treatment of peptic ulcers. Relieving indigestion and heartburn.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Magnesium trisilicate works by increasing the pH of gastric juice via a neutralisation reaction. It also precipitates colloidal silica, which can coat gastrointestinal mucosa conferring further protection.

Mechanism of action

The gelatinous silicon dioxide, formed by the reaction of magnesium trisilicate with gastric contents is said to protect ulcerated mucosal surfaces and favor healing.

Absorption

The hydrated silicon dioxide formed in the stomach and passes into the intestinal track where, silica can be partly absorbed.

Volume of distribution

The hydrated silicon dioxide formed in the stomach and passes into the intestinal track.

Protein binding

33%

Metabolism
Not Available
Route of elimination

Excreted in the urine.

Half-life

16-20 hours

Clearance

Maximum magnesium clearance is directly proportional to creatinine clearance.

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Adequate doses of magnesium trisilicate may cause diarrhea due to the action of soluble magnesium salts in the enteric tract. Approx 5% of the magnesium is absorbed.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
AcetaminophenMagnesium trisilicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Magnesium trisilicate.
AcetophenazineMagnesium trisilicate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
AclidiniumThe therapeutic efficacy of Magnesium trisilicate can be decreased when used in combination with Aclidinium.
AcrivastineMagnesium trisilicate may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Magnesium trisilicate hydrateC2E1CI501T39365-87-2FSBVERYRVPGNGG-UHFFFAOYSA-N
Active Moieties
NameKindUNIICASInChI Key
Magnesium cationionicT6V3LHY83822537-22-0JLVVSXFLKOJNIY-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Virus Blocker Cl-40Stick80 g/100gTopicalJOONGWAN LIFE & STYLE Co.ltd2020-10-31Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AIRTABMagnesium trisilicate (350 MG) + Aluminum hydroxide (250 MG)TabletOralบริษัท มิลลิเมด จำกัด จำกัด2003-07-17Not applicableThailand flag
Alka Phenyl TabMagnesium trisilicate (150 mg / tab) + Aluminum hydroxide (100 mg / tab) + Phenylbutazone (100 mg / tab)TabletOralDuchesnay Inc.1978-12-311997-08-11Canada flag
Alka Phenylbutazone TabMagnesium trisilicate (150 mg / tab) + Aluminum hydroxide (100 mg / tab) + Phenylbutazone (100 mg / tab)TabletOralPro Doc Limitee1974-12-311997-08-14Canada flag
ALLUMAG M TABLETMagnesium trisilicate (250 mg) + Aluminum hydroxide (120 mg)TabletOralPHARMATECH RESOURCES (FE) PTE. LTD.1997-09-25Not applicable
ALLUMAG M TABLETMagnesium trisilicate (250 mg) + Aluminum hydroxide (120 mg)TabletOralCHULIA PHARMA SDN BHD2017-10-032019-09-11Malaysia flag
ALLUMAG MPS TABLETMagnesium trisilicate (100 mg) + Aluminum hydroxide (300 mg) + Simethicone (50 mg)TabletOralCHULIA PHARMA SDN BHD2017-10-032019-09-11Malaysia flag
ALLUMAG MPS TABLETMagnesium trisilicate (100 mg) + Aluminum hydroxide (300 mg) + Simethicone (50 mg)TabletOralPHARMATECH RESOURCES (FE) PTE. LTD.1997-09-22Not applicable
ALUMAG PLUS TABLETSMagnesium trisilicate (250 mg) + Aluminum hydroxide (250 mg) + Simethicone (30 mg)TabletOralBEACONS PHARMACEUTICALS PTE. LTD.1989-06-06Not applicable
ALUMAG TABLETSMagnesium trisilicate (250 mg) + Aluminum hydroxide (250 mg)TabletOralBEACONS PHARMACEUTICALS PTE. LTD.1989-06-08Not applicable
ALUSIL MPS TABLETMagnesium trisilicate (300 mg) + Aluminum hydroxide (100 mg) + Simethicone (20 mg)TabletOralZONTRON PHARMACEUTICALS SDN. BHD.2020-09-08Not applicableMalaysia flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Virus Blocker Cl-40Magnesium trisilicate hydrate (80 g/100g)StickTopicalJOONGWAN LIFE & STYLE Co.ltd2020-10-31Not applicableUS flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal silicates. These are inorganic compounds in which the largest oxoanion is silicate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal oxoanionic compounds
Sub Class
Alkaline earth metal silicates
Direct Parent
Alkaline earth metal silicates
Alternative Parents
Miscellaneous silicates / Metalloid salts / Inorganic salts / Inorganic oxides
Substituents
Alkaline earth metal silicate / Inorganic metalloid salt / Inorganic oxide / Inorganic salt / Silicate
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
FML8G1U0Y3
CAS number
14987-04-3
InChI Key
GXGAKHNRMVGRPK-UHFFFAOYSA-N
InChI
InChI=1S/2Mg.O8Si3/c;;1-9(2)7-11(5,6)8-10(3)4/q2*+2;-4
IUPAC Name
dimagnesium(2+) ion {[dioxido({[oxido(oxo)silyl]oxy})silyl]oxy}silanoylolate
SMILES
[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O

References

General References
  1. Toxnet [Link]
  2. Toxnet [Link]
  3. Sciencedirect [Link]
KEGG Drug
D03271
PubChem Compound
5311266
PubChem Substance
310265174
ChemSpider
4470779
RxNav
29170
ChEMBL
CHEMBL2096633
Wikipedia
Magnesium_trisilicate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentGastro-esophageal Reflux Disease (GERD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral300 mg
Tablet
TabletOral250 mg
TabletOral
SuspensionOral50 mg/ml
Tablet, chewableOral
SolutionOral
Suspension
TabletOral120 mg
SuspensionOral5 % w/v
SuspensionOral400 mg/5ml
SuspensionOral
StickTopical80 g/100g
TabletOral200 mg
Capsule
Powder
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-2.7ChemAxon
pKa (Strongest Acidic)2.65ChemAxon
pKa (Strongest Basic)-7.7ChemAxon
Physiological Charge-4ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area144.84 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity11.36 m3·mol-1ChemAxon
Polarizability11.91 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Drug created at October 29, 2015 15:58 / Updated at June 12, 2020 16:52